Key result
Review updates evaluation and optimal management of ADHF, projected to affect ~8 million Americans.
Why the study?
The prevalence and costs of acute decompensated heart failure are increasing, and recent studies have begun to address its management, necessitating an updated clinical review.
Answers are grounded in this paper and cite their sources.
This review provides an update on the evaluation and optimal management of acute decompensated heart failure.
Acute decompensated heart failure (ADHF) continues to increase in prevalence and is associated with substantial mortality and morbidity including frequent hospitalizations. The American Heart Association is predicting that more than eight million Americans will have heart failure by 2030 and that the total direct costs associated with the disease will rise from $21 billion in 2012 to $70 billion in 2030. The increase in the prevalence and cost of HF is primarily the result of shifting demographics and a growing population. Although many large, randomized, controlled clinical trials have been conducted in patients with chronic heart failure, it was not until recently that a growing number of studies began to address the management of ADHF. It is the intent of this review to update the clinician regarding the evaluation and optimal management of ADHF.
No takes yet. Share an insight, caveat, or question.
Teerlink et al. (2014) conducted a review in Acute decompensated heart failure. This review updates clinicians on the evaluation and optimal management of acute decompensated heart failure, which is projected to affect over 8 million Americans and cost $70 billion by 2030.
Synapse has enriched 10 related papers. Consider them for comparative context: